Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 113
Filtrar
1.
New Microbes New Infect ; 20: 43-50, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29158908

RESUMEN

A cross-sectional serosurvey was performed to identify environmental features or practices of dairy farms associated with risk for exposure to vaccinia-like viruses in dairy cattle in Brazil. Sera from 103 cows from 18 farms in Minas Gerais state were examined for Orthopoxvirus-neutralizing antibodies. A database of 243 binary or multiple-selection categorical variables regarding the physical features and surrounding ecology of each property was obtained. Thirteen of 46 presumptive predictor variables were found to be significantly associated with Orthopoxvirus serostatus by univariate logistic regression methods. Use of teat sanitizer and having felids on the property were independently associated with virus exposure by multivariable analysis. Rodents have long been suspected of serving as maintenance reservoirs for vaccinia-like viruses in Brazil. Therefore, domestic felids are not only effective predators of small rodent pests, but also their urine can serve as a deterrent to rodent habitation in buildings such as stables and barns. These results corroborate previous evidence of the high significance of rodents in the Vaccinia virus transmission cycle, and they also raise questions regarding the common use of teat sanitizers in dairy production areas.

2.
Epidemiol Infect ; 135(4): 583-91, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-16938142

RESUMEN

The United States national mortality statistics and HIV/AIDS surveillance data were analysed to determine trends in encephalitis-associated deaths and to assess the impact of HIV infection on those deaths during 1979-1998, a period when ICD-9 codes were used for coding deaths in the United States. A total of 25125 encephalitis deaths were reported; 4779 of them (19%) had concurrent HIV infection. Overall encephalitis death rates remained stable, but they increased for groups where HIV infection was common and declined or remained unchanged for others. For persons without HIV infection, the rates declined in all demographic groups. Encephalitis deaths in HIV-infected persons followed general trends for HIV deaths in the United States. The rates in the HIV-infected population were several hundred- to thousand-fold higher than in the HIV-uninfected population. HIV infection was largely responsible for the lack of overall decline in the considerable mortality associated with encephalitis in the United States during 1979-1998.


Asunto(s)
Causas de Muerte , Infecciones Bacterianas del Sistema Nervioso Central/complicaciones , Enfermedades Virales del Sistema Nervioso Central/complicaciones , Encefalitis , Mortalidad/tendencias , Adolescente , Adulto , Niño , Preescolar , Encefalitis/epidemiología , Encefalitis/etiología , Encefalitis/mortalidad , Femenino , Infecciones por VIH/complicaciones , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo
3.
Ann N Y Acad Sci ; 1078: 118-9, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17114690

RESUMEN

The epidemiologic features are described of cases of human monocytic ehrlichiosis and human granulocytic anaplasmosis in the United States.


Asunto(s)
Anaplasmosis/epidemiología , Ehrlichiosis/epidemiología , Distribución por Edad , Anaplasmosis/sangre , Ehrlichiosis/sangre , Femenino , Humanos , Incidencia , Masculino , Monocitos/microbiología , Estados Unidos/epidemiología
4.
Neurology ; 66(3): 439-41, 2006 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-16476950

RESUMEN

The occurrence of Creutzfeldt-Jakob disease (CJD) among American Indians and Alaska Natives in the United States was evaluated using national multiple cause-of-death data and medical information obtained from state health departments. Twelve CJD deaths were identified for 1981 through 2002, and the average annual age-adjusted death rate was 0.47 per million population. This rate was significantly lower than that for whites and similar to the rate for African Americans.


Asunto(s)
Síndrome de Creutzfeldt-Jakob/mortalidad , Indígenas Norteamericanos/estadística & datos numéricos , Inuk/estadística & datos numéricos , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Alaska/epidemiología , Humanos , Persona de Mediana Edad , Estados Unidos/epidemiología
5.
Clin Diagn Lab Immunol ; 12(2): 273-9, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15699422

RESUMEN

We examined sera from 42 patients 1 to 30 months of age for rotavirus immunoglobulin M (IgM), IgA, IgG, and IgG subclasses and sought to determine if serum antibody could serve as a reliable marker for prediction of disease severity. Infants in the first few months of life usually had high maternal IgG titers and, when they were infected with rotavirus, had low IgM titers or no IgM in acute-phase sera and poor seroconversions 3 weeks later, suggesting that maternal antibodies had inhibited viral replication and antibody responses. All patients > or =6 months of age had IgM in acute-phase sera, indicating that IgM is a good marker for acute rotavirus infection. IgG was the best overall predictor of an infection, as the convalescent-phase sera of 81% of the patients had a fourfold rise in the IgG titer. IgA titers in convalescent-phase sera and conversion rates were higher among patients > or =12 months of age than among children younger than 12 months. IgG1 was the predominant subclass detected in the acute-phase sera of some children and in all 28 convalescent-phase serum samples examined. Patients with preexisting acute-phase IgG titers of > or =100 or > or =200 had diarrhea that was less severe or of a shorter duration. These results indicate that serum IgG is the most reliable marker for seroconversion and is a consistent proxy for protection against severe disease.


Asunto(s)
Anticuerpos Antivirales/sangre , Diarrea/diagnóstico , Inmunoglobulina G/sangre , Infecciones por Rotavirus/diagnóstico , Preescolar , Diarrea/inmunología , Diarrea/prevención & control , Femenino , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , Inmunoglobulina M/sangre , Inmunoglobulina M/inmunología , Lactante , Recién Nacido , Masculino , Infecciones por Rotavirus/inmunología , Infecciones por Rotavirus/prevención & control
6.
Transfusion ; 44(7): 967-72, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15225234

RESUMEN

BACKGROUND: In January 2003, white particulate matter (WPM) was detected in blood components. Because the composition and cause of WPM was not understood at that time, there was uncertainty about whether WPM could endanger patient safety. To investigate possible adverse patient events associated with WPM, transfusion reaction rates were examined. STUDY DESIGN AND METHODS: A questionnaire was distributed to Georgia medical centers. Data collected included the number of components transfused and reported adverse reactions by component type from January 2002 through January 2003, and date, reaction type, and blood supplier for events in January 2003. RESULTS: Of 124 transfusion services contacted, 108 (87%) responded. During the survey period, there were 1213 reported transfusion reactions and 528,412 units transfused, or 2.3 reactions per 1000 units transfused; for RBCs, 2.4 (range, 1.8-3.1); plasma, 1.5 (range, 0.6-3.5); and PLTs, 3.4 (2.1-5.4) per 1000 units. Transfusion reaction rates by component for January 2003 did not differ significantly from the rate for January 2002 or for the calendar year. The 86 reported reactions that occurred in January 2003 were attributed to bacterial contamination (n = 2, 2.3%), other febrile nonhemolytic (n = 49, 57.0%), allergic (n = 14, 16.3%), and "other" reactions (n = 21, 24.4%); the proportions of reaction types did not differ significantly during the month. CONCLUSION: No overall changes in reported adverse reaction rates occurred over the survey period or in the proportion of reaction types during January 2003 when WPM was detected. Statewide surveillance of transfusion reactions could be useful to evaluate potential threats to blood safety.


Asunto(s)
Recolección de Muestras de Sangre , Reacción a la Transfusión , Humanos , Estudios Retrospectivos , Riesgo , Seguridad
7.
Clin Diagn Lab Immunol ; 10(6): 995-1001, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14607858

RESUMEN

Rotavirus is the most common cause of severe gastroenteritis in young children, but the pathogenesis and immunity of this disease are not completely understood. To examine the host response to acute infection, we collected paired serum specimens from 30 children with rotavirus diarrhea and measured the levels of nine cytokines (interleukin-1beta [IL-1beta], IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, gamma interferon [IFN-gamma], and tumor necrosis factor alpha [TNF-alpha]) using a microsphere-based Luminex Flowmetrix system. Patients with acute rotavirus infection had elevated median levels of seven cytokines in serum, and of these, the levels of three (IL-6, IL-10, and IFN-gamma) were significantly (P < 0.05) higher than those in serum from control children without diarrhea. Patients with fever had significantly (P < 0.05) higher levels of IL-6 in serum than control children, and those with fever and more episodes of diarrhea had significantly (P < 0.05) higher levels of TNF-alpha than those without fever and with fewer episodes of diarrhea. We further demonstrated a negative association (P < 0.05) between the levels of IL-2 and the number of stools on the day on which the first blood sample was collected. Finally, patients with vomiting had significantly (P < 0.05) lower levels of IFN-gamma than those without vomiting. Our pilot study provides evidence that the types and magnitudes of cytokine responses to rotavirus infection in children influence or reflect the clinical outcome of disease. These findings suggest that certain cytokines may play an important role in the pathogenesis of and the protection against rotavirus disease in children and, consequently, may provide directions and insights that could prove critical to the prevention or treatment of this important disease.


Asunto(s)
Citocinas/sangre , Infecciones por Rotavirus/inmunología , Estudios de Casos y Controles , Diarrea/sangre , Femenino , Fiebre/sangre , Humanos , Lactante , Interferón gamma/sangre , Interleucina-10/sangre , Interleucina-6/sangre , Masculino , Estudios Prospectivos , Infecciones por Rotavirus/sangre , Infecciones por Rotavirus/etiología
8.
Clin Infect Dis ; 34(3): 293-304, 2002 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-11774075

RESUMEN

To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. HPS was subsequently laboratory confirmed in 30 persons and not confirmed in 105 persons with adequate specimens. Patients with HPS were significantly more likely than were hantavirus-negative patients to report myalgias from onset of symptoms through hospitalization, nausea at outpatient presentation, and diarrhea and nausea at the time of hospitalization; they were significantly less likely to report respiratory symptoms early in the illness. The groups did not differ with regard to time from the onset of illness to the point at which they sought care; time from onset, hospitalization, or enrollment to death was significantly shorter for patients with HPS. At the time of hospitalization, patients with HPS more commonly had myelocytes, metamyelocytes, or promyelocytes on a peripheral blood smear, and significantly more of them had thrombocytopenia, hemoconcentration, and hypocapnia. Patterns of clinical symptoms, the pace of clinical evolution, and specific clinical laboratory parameters discriminated between these 2 groups.


Asunto(s)
Antivirales/uso terapéutico , Infecciones por Hantavirus/tratamiento farmacológico , Enfermedades Pulmonares/tratamiento farmacológico , Ribavirina/uso terapéutico , Antivirales/efectos adversos , Análisis de los Gases de la Sangre , Electrólitos , Femenino , Orthohantavirus , Humanos , Infusiones Intravenosas , Pruebas de Función Renal , Pruebas de Función Hepática , Enfermedades Pulmonares/virología , Masculino , Recuento de Plaquetas , Tiempo de Protrombina , Análisis de Regresión , Ribavirina/efectos adversos , Factores de Tiempo
9.
J Infect Dis ; 184(11): 1437-44, 2001 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-11709786

RESUMEN

Epidemiologic and clinical characteristics of fatal and nonfatal cases of Rocky Mountain spotted fever (RMSF) were compared to identify risk factors for death caused by this disease. Confirmed and probable RMSF cases reported through US national surveillance for 1981-1998 were analyzed. Among 6388 RMSF patients, 213 died (annual case-fatality rate, 3.3%; range, 4.9% in 1982 to 1.1% in 1996). Use of tetracycline-class antibiotics for treatment of RMSF increased significantly in the 1990s, compared with use in the 1980s. Older patients, patients treated with chloramphenicol only, patients for whom tetracycline antibiotics were not the primary therapy, and patients for whom treatment was delayed > or =5 days after the onset of symptoms were at higher risk for death. Although the case-fatality rate was lower in the 1990s than in the 1980s, risk factors for fatal RMSF were similar. Despite the availability of effective antibiotics, RMSF-related deaths continue to occur because of delayed diagnosis and failure to use appropriate therapy.


Asunto(s)
Antibacterianos/uso terapéutico , Fiebre Maculosa de las Montañas Rocosas/mortalidad , Adolescente , Adulto , Factores de Edad , Anciano , Niño , Preescolar , Femenino , Hospitalización , Humanos , Lactante , Cinética , Masculino , Persona de Mediana Edad , Factores de Riesgo , Fiebre Maculosa de las Montañas Rocosas/diagnóstico , Fiebre Maculosa de las Montañas Rocosas/tratamiento farmacológico , Tetraciclinas , Resultado del Tratamiento , Estados Unidos/epidemiología
10.
Pediatr Infect Dis J ; 20(7): 646-53, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11465835

RESUMEN

BACKGROUND: Human parainfluenza viruses 1 through 3 (HPIV-1-3) are important causes of respiratory tract infections in young children. This study sought to provide current estimates of HPIV-1-3-associated hospitalizations among US children. METHODS: Hospitalizations for bronchiolitis, bronchitis, croup and pneumonia among children age <5 years were determined for the years 1979 through 1997 using the National Hospital Discharge Survey. Average annual hospitalizations during the last 4 years of the study for each of these four diseases were multiplied by the proportions of each disease associated with HPIV-1-3 infection (as previously reported in hospital-based studies) to estimate hospitalizations potentially associated with HPIV-1-3 infections. Seasonal trends in HPIV-1-3-associated hospitalizations were compared with HPIV detections in the National Respiratory and Enteric Virus Surveillance System, which prospectively monitors respiratory viral detections throughout the United States. RESULTS: The proportions of hospitalizations associated with HPIV infection for each disease varied widely in the 6 hospital-based studies we selected. Consequently our annual estimated rates of hospitalization were broad: HPIV-1, 0.32 to 1.59 per 1,000 children; HPIV-2, 0.10 to 0.86 per 1,000 children; and HPIV-3, 0.48 to 2.6 per 1,000 children. Based on these data HPIV-1 may account for 5,800 to 28,900 annual hospitalizations; HPIV-2 for 1,800 to 15,600 hospitalizations; and HPIV-3 for 8,700 to 52,000 hospitalizations. CONCLUSIONS: We provide broad, serotype-specific estimates of US childhood hospitalizations associated with HPIV infections. More precise estimates of HPIV-associated hospitalizations would require large prospective studies of HPIV-associated diseases by more sensitive viral testing methods, such as polymerase chain reaction techniques.


Asunto(s)
Bronquiolitis Viral/epidemiología , Crup/epidemiología , Hospitalización/estadística & datos numéricos , Neumonía Viral/epidemiología , Infecciones por Respirovirus/epidemiología , Bronquiolitis Viral/diagnóstico , Preescolar , Crup/diagnóstico , Humanos , Lactante , Virus de la Parainfluenza 1 Humana/aislamiento & purificación , Virus de la Parainfluenza 2 Humana/aislamiento & purificación , Virus de la Parainfluenza 3 Humana/aislamiento & purificación , Neumonía Viral/diagnóstico , Infecciones por Respirovirus/diagnóstico , Factores de Riesgo , Estaciones del Año , Factores Socioeconómicos , Estados Unidos/epidemiología
11.
Am J Hematol ; 66(3): 159-66, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11279621

RESUMEN

Since a significant number of lymphomas have been associated with the human immunodeficiency virus (HIV), the purpose of this study was to describe the impact of HIV infection on non-Hodgkin's lymphoma (NHL) mortality trends and demographics. Multiple-cause-of-death data for the United States from 1979 through 1996 were obtained from the National Center for Health Statistics, Centers for Disease Control and Prevention. Annual NHL deaths rates for the United States were calculated as the number of NHL deaths per 100,000 persons, based on estimates of the U.S. resident population. The time periods 1979-1982, 1986-1989, and 1993-1996 were examined for changes over time. To describe NHL and HIV infection mortality, the characteristics of NHL deaths with HIV infection listed anywhere on the death records were examined beginning in 1987. This study found that despite reports of a lower incidence rate of NHL among blacks with HIV/AIDS, death rates from lymphomas associated with HIV/AIDS have markedly increased in black males and females over time. It was also noted that in agreement with other studies, this study documented a decrease in NHL/HIV mortality in 1996.


Asunto(s)
Linfoma no Hodgkin/mortalidad , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Adolescente , Adulto , Anciano , Población Negra , Centers for Disease Control and Prevention, U.S. , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Tasa de Supervivencia , Estados Unidos , Población Blanca
12.
Am J Hematol ; 66(4): 229-40, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11279632

RESUMEN

Because of changes in factor replacement therapy and in treatment of human immunodeficiency virus (HIV) infection, we examined death record data for persons with hemophilia A in the United States to evaluate effects of HIV infection on age and causes of death. Multiple cause-of-death data from 1968 through 1998 were examined to assess death rates for persons with hemophilia A. ICD-9 coded causes of death from 1979 through 1998 were examined to assess long-term trends. From 1979 through 1998, 4,781 deaths among persons with hemophilia A were reported, of which 2,254 (47%) had HIV-related disease listed as a cause of death. In the late 1980s, mortality among persons with hemophilia A increased markedly, and the age-adjusted death rate peaked at 1.5 per 1,000,000 population in 1992. Median age at death decreased from 55 years in 1979-1982 to 40.5 years in 1987-1990, and increased to 46 years in 1995-1998. In the period 1995-1998, the median age of hemophilia A decedents with HIV-related disease was 33 years, compared to 72 years for those without HIV-related disease; the most frequently listed causes of death for those without HIV-related disease were hemorrhagic and circulatory phenomena; the most frequently listed for those with HIV-related disease were diseases of liver and the respiratory system. From 1995 to 1998, hemophilia A-associated deaths decreased by 41%, with a 78% decrease among those who had HIV-related disease. Although HIV infection has adversely effected mortality for persons with hemophilia A, the marked recent decrease in the death rate among persons with hemophilia A appears to reflect advances in care for those with HIV-related disease and is consistent with a decline in HIV mortality observed in the general population.


Asunto(s)
Infecciones por VIH/complicaciones , Hemofilia A/mortalidad , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/mortalidad , Infecciones Oportunistas Relacionadas con el SIDA/prevención & control , Adolescente , Adulto , Distribución por Edad , Anciano , Antibacterianos/uso terapéutico , Fármacos Anti-VIH/uso terapéutico , Antivirales/uso terapéutico , Causas de Muerte , Niño , Preescolar , Comorbilidad , Certificado de Defunción , Grupos Diagnósticos Relacionados , Femenino , Infecciones por VIH/mortalidad , Hemofilia A/complicaciones , Hemorragia/etiología , Hemorragia/mortalidad , Hepatitis Viral Humana/etiología , Hepatitis Viral Humana/mortalidad , Humanos , Lactante , Recién Nacido , Esperanza de Vida , Masculino , Persona de Mediana Edad , Mortalidad/tendencias , Grupos Raciales , Trastornos Respiratorios/etiología , Trastornos Respiratorios/mortalidad , Estudios Retrospectivos , Distribución por Sexo , Estados Unidos/epidemiología
13.
Am J Public Health ; 91(3): 425-31, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11236408

RESUMEN

OBJECTIVES: This study sought to describe trends in hospitalizations associated with infectious diseases among American Indians and Alaska Natives. METHODS: Infectious disease hospitalizations and rates among American Indians and Alaska Natives from 1980 through 1994 were examined via Indian Health Service hospital discharge data and compared with published trends for the general US population. RESULTS: Annual hospitalization rates for infectious diseases among American Indians and Alaska Natives decreased by 31.0% between 1980 and 1994. Infectious disease hospitalizations accounted for 16.3% of all hospitalizations in 1980 and 21.2% in 1994, an increase of 30.1%. In 1994, the age-adjusted infectious disease hospitalization rate for American Indians and Alaska Natives was 1863 per 100,000 population, approximately 21% greater than that for the general US population. CONCLUSIONS: Hospitalization trends for infectious diseases show that there has been improvement in the health status of American Indians and Alaska Natives but also indicate that this population has a higher infectious disease burden than the general US population.


Asunto(s)
Hospitalización/tendencias , Indígenas Norteamericanos/estadística & datos numéricos , Infecciones/epidemiología , Inuk/estadística & datos numéricos , Adolescente , Adulto , Anciano , Alaska/etnología , Niño , Preescolar , Femenino , Mortalidad Hospitalaria , Humanos , Lactante , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Estados Unidos/epidemiología
14.
Pediatr Infect Dis J ; 20(1): 14-9, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11176561

RESUMEN

OBJECTIVE: To assess the financial and clinical burden of diarrhea- and rotavirus-associated disease among a population of privately insured US children. METHODS: For the period 1993 through 1996, we analyzed medical claims data from a large, administrative database containing information on approximately 300,000 children <5 years of age to examine trends in, and costs associated, with hospitalizations and outpatient visits for diarrhea. RESULTS: An annual average of 1,186 diarrhea-associated hospitalizations (35 per 10,000 children <5 years) and 33 386 outpatient visits (943 per 10,000 children <5 years) were reported, accounting for 4% of all hospitalizations and 2% of all outpatient visits among children <5 years of age. Diarrhea-associated hospitalizations and outpatient visits showed a distinct winter-spring peak consistent with that of rotavirus infection. The excess of diarrhea-associated events occurring during the winter-spring peak accounted for an average of 50% of all diarrhea-associated hospitalizations and 18% of all diarrhea-associated outpatient visits. The median cost (in 1998 constant dollars) of a diarrhea-associated hospitalization was $2,307, and that for a rotavirus-associated hospitalization was $2,303. Median costs of diarrhea- and rotavirus-associated outpatient visits were $47 and $57, respectively. CONCLUSIONS: Diarrhea is an important cause of morbidity in this insured population of young children. The epidemiologic features of diarrhea-associated events suggest that rotavirus is an important contributor to the overall morbidity from diarrhea. These disease burden and cost estimates should provide useful information with which to assess the costs and benefits of future interventions for rotavirus-associated illness.


Asunto(s)
Costo de Enfermedad , Diarrea/economía , Costos de Hospital , Hospitalización/economía , Servicio Ambulatorio en Hospital/economía , Infecciones por Rotavirus/economía , Preescolar , Bases de Datos Factuales , Diarrea/epidemiología , Hospitalización/estadística & datos numéricos , Hospitalización/tendencias , Humanos , Lactante , Seguro de Salud , Morbilidad , Servicio Ambulatorio en Hospital/estadística & datos numéricos , Servicio Ambulatorio en Hospital/tendencias , Infecciones por Rotavirus/epidemiología , Estaciones del Año , Estados Unidos/epidemiología , Virosis/economía , Virosis/epidemiología
15.
J Infect Dis ; 183(1): 16-22, 2001 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-11076709

RESUMEN

A 1985 estimate that 4500 respiratory syncytial virus (RSV)-associated deaths occur annually among US children has not been updated using nationally representative data. Thus, 1979-1997 multiple cause-of-death records for children <5 years old listing bronchiolitis, pneumonia, or any respiratory tract disease were examined. Deaths among children associated with any respiratory disease declined from 4631 in 1979 to 2502 in 1997. During the 19-year study period, 1806 bronchiolitis-associated deaths occurred (annual mean, 95 deaths; range, 66-127 deaths). Of these deaths, 1435 (79%) occurred among infants <1 year old. Congenital heart disease, lung disease, or prematurity was listed in death records of 179 (9.9%), 99 (5.5%), and 76 (4.2%) children dying with bronchiolitis, respectively. By applying published proportions of children hospitalized for bronchiolitis or pneumonia who were RSV-infected to bronchiolitis and pneumonia deaths, it was estimated that < or =510 RSV-associated deaths occurred annually during the study period, fewer than previously estimated.


Asunto(s)
Bronquiolitis/mortalidad , Infecciones por Virus Sincitial Respiratorio/mortalidad , Virus Sincitial Respiratorio Humano , Preescolar , Femenino , Cardiopatías Congénitas/mortalidad , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Masculino , Estaciones del Año , Estados Unidos/epidemiología
17.
Hawaii Med J ; 59(9): 362-5, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11055116

RESUMEN

OBJECTIVE: To estimate the burden of diarrhea-associated hospitalizations among children in Hawaii. DESIGN: Retrospective analysis of hospital discharge records. PATIENTS: Children from 1 month through 4 years of age with a diarrhea-associated diagnosis listed on the hospital discharge record in Hawaii. SETTING: Acute care hospitals in the state of Hawaii, 1994 through 1997. RESULTS: During 1994-1997, 2288 children (11.3% of all hospitalizations for children < 5 years of age) had a diarrhea-associated diagnosis listed at hospital discharge. The average annual incidence (per 10,000 children) of diarrhea-associated hospitalizations was 62.3; the incidence was higher for children < 1 year (101.6) than for those 1 through 4 years of age (52.7). Rates for Hawaii were lower than national rates during 1993 through 1995 (US annual rate of 89 per 10,000 children). The median length of hospital stay was 2 days for diarrhea-associated hospitalizations, and 3 days for hospitalizations specifically associated with rotavirus-related diarrhea. Diarrhea-associated hospitalizations were highest during the period December through June. CONCLUSIONS: Diarrhea is an important cause of hospitalization among children in Hawaii, where approximately 1 in 32 children may be hospitalized by 5 years of age. The age-specific and temporal trends reported here are consistent with those previously described for rotavirus-associated hospitalizations, suggesting that this pathogen is a major contributor to the overall morbidity from diarrhea.


Asunto(s)
Diarrea Infantil/epidemiología , Diarrea/epidemiología , Hospitalización/estadística & datos numéricos , Preescolar , Hawaii/epidemiología , Humanos , Lactante , Tiempo de Internación/estadística & datos numéricos , Estudios Retrospectivos , Infecciones por Rotavirus/epidemiología
18.
Pediatr Infect Dis J ; 19(9): 828-32, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11001104

RESUMEN

BACKGROUND: Kawasaki syndrome (KS) causes an acute vasculitis of unknown etiology. It is a leading cause of acquired heart disease of children in Japan and the United States. METHODS: We examined the incidence of KS in a well-defined population group of children < or =6 years of age, using data collected through the Vaccine Safety Datalink (VSD) project. The VSD database contains information on >1 million children enrolled in four West Coast health maintenance organizations (HMOs). RESULTS: During 1993 through 1996 a total of 234 physician-diagnosed KS patients were reported in the 4 HMOs; 152 (65.0%) were boys and 195 (83.3%) were <5 years of age. The incidence of KS among children <5 years of age in the HMOs ranged from 9.0 to 19.1 per 100,000 person years. KS incidence was higher among boys in 3 of the sites. In the 2 sites with the highest number of KS patients, a seasonal occurrence of KS in winter and early spring was observed. Overall 226 (96.6%) of the KS patients were reported to have been hospitalized; hospitalization rates for children <5 years of age ranged from 9.0 to 16.8 per 100,000 person years. CONCLUSIONS: The incidence of KS in the HMOs was similar to that reported in other population-based studies in the United States and higher than estimates for Australia and several European countries.


Asunto(s)
Hospitalización/estadística & datos numéricos , Síndrome Mucocutáneo Linfonodular/epidemiología , Factores de Edad , California/epidemiología , Niño , Preescolar , Estudios Epidemiológicos , Femenino , Sistemas Prepagos de Salud/estadística & datos numéricos , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Oregon/epidemiología , Estaciones del Año , Washingtón/epidemiología
19.
Vaccine ; 19(2-3): 308-18, 2000 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-10930686

RESUMEN

The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996-97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36-81%) for recipients of a combination of the vaccines compared with 51% (95%CI, -17-79%) for recipients of live vaccine alone and 50% (95%CI, -26-80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.


Asunto(s)
Vacunas contra la Influenza/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antivirales/sangre , Método Doble Ciego , Pruebas de Inhibición de Hemaglutinación , Humanos , Inmunoglobulina A Secretora/análisis , Persona de Mediana Edad , Casas de Salud , Vacunación , Vacunas Atenuadas/inmunología , Vacunas Combinadas/inmunología
20.
Arch Pediatr Adolesc Med ; 154(8): 804-8, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10922277

RESUMEN

OBJECTIVES: To estimate the incidence and describe recent trends of Kawasaki syndrome (KS) in 2 different areas of the United States. METHODS: Retrospective analysis of Hawaii and Connecticut State KS hospital discharge records for children younger than 5 years. RESULTS: In Hawaii, 175 KS hospitalizations for children younger than 5 years were reported during 1994 through 1997; the annual hospitalization rate per 100,000 children was 47.7. The rate for Hawaiian children younger than 1 year (83.2) was greater than that for 1- to 4-year-old children (39.0), and most hospitalizations occurred prior to age 2 years (median age, 17 months). In Connecticut, 171 KS hospitalizations for children younger than 5 years were reported during 1993 through 1996; the annual hospitalization rate per 100,000 children was 18.8, and the median age at hospitalization was 28 months. For both states, most hospitalizations were for boys. Although no clear seasonality was apparent, monthly peaks occurred in some of the years from December through March. CONCLUSIONS: Kawasaki syndrome seems to remain an endemic disease in the United States. A high KS annual hospitalization rate was seen in Hawaii, especially in children younger than 1 year, whereas in Connecticut, the KS rate was more consistent with those previously reported in the continental United States. Arch Pediatr Adolesc Med. 2000;154:804-808


Asunto(s)
Hospitalización/estadística & datos numéricos , Síndrome Mucocutáneo Linfonodular/epidemiología , Preescolar , Connecticut/epidemiología , Femenino , Hawaii/epidemiología , Humanos , Incidencia , Lactante , Masculino , Estaciones del Año
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA